<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-114142</identifier>
<setSpec>1134-3230</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Factors associated with optimal glycemic control in patients with insulin pump therapy and continuous glucose monitoring in real time</dc:title>
<dc:description xml:lang="en">Objective: When used with continuous glucose monitoring (CGM) and bolus estimation algorithms, many patients on insulin pump therapy achieve near-euglycemia. We evaluated the usage patterns of integrated pump/CGM technology that are associated with A1C levels &lt; 7%. Methods: Data from 217 patients (age &gt; 11 years, 53.5% male, 91.7% with type 1 diabetes, all with &gt; 3 months pump experience) receiving care at a teaching hospital in Bogotá, Colombia, were analyzed. Data included insulin delivery, A1C levels, severe hypoglycemic events, use of CGM, completion of diabetes education courses, and the frequency of blood glucose checks. All patients received training on the use of the pump, and most (73.7%) received additional training on carbohydrate counting, basal rate adjustments, and use of CGM data. Results: Initiation of pump therapy was associated with decreases in A1C, insulin use, and severe hypoglycemic events (all P &lt;0 .001). Pump and CGM-specific behaviors associated with lower A1C included the use of a dose estimation algorithm for &gt; 80% of bolus doses and use of CGM sensors &gt; 80% of the time (both P &lt;0 .005). Lower A1C was also associated with the completion of additional training, age &gt; 18, use of the Paradigm 722 pump with an integrated CGM device, use of CGM-based alarms, A1c &gt;7% before pump therapy, and more frequent blood glucose checks (all P &lt; 0.05). Many (45.6%) patients reached A1c &amp;#8804; 7% with pump therapy. Conclusions: Patient education, with an A1c below 7% before sensor-augmented pump therapy, when combined with consistent use of CGM sensors and bolus estimation algorithms, leads to favorable reductions in A1C beyond those achieved with pump therapy alone (AU)</dc:description>
<dc:creator>Veloza, Angélica</dc:creator>
<dc:creator>Grizales, Ana María</dc:creator>
<dc:creator>Marín, Alejandro</dc:creator>
<dc:creator>Gómez, Ana María</dc:creator>
<dc:creator>Muñoz, Oscar Mauricio</dc:creator>
<dc:creator>Rondón, Martín Alonso</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Cuando se utiliza monitorización continua de glucosa (MCG) y algoritmos de estimación de bolos, muchos pacientes en terapia con bomba de insulina alcanzan euglucemia. Evaluamos patrones de uso en integración de tecnología de bomba/MCG asociados con niveles de HbA1c &lt; 7%. Métodos: Analizamos datos de 217 pacientes (edad &gt; 11 años; 53,5% hombres; 91,7% con diabetes tipo 1;  &gt; 3 meses de experiencia en bomba) en manejo en un hospital universitario de Bogotá, Colombia, incluyendo aplicación de insulina, HbA1c, eventos hipoglucémicos severos, uso de MCG, culminación de cursos educativos en diabetes y frecuencia de glucometrías. Todos los pacientes recibieron entrenamiento para uso de bomba y la mayoría (73,7%) entrenamiento adicional en conteo de hidratos de carbono, ajustes de tasa basal y uso de datos de MCG. Resultados: El inicio de terapia con bomba se asoció a disminución de HbA1c, uso de insulina y eventos hipoglucémicos severos (p &lt; 0,001). Conductas específicas con bomba-MCG asociadas con menor A1c incluyeron uso de algoritmos de estimación de dosis en &gt; 80% de los bolos y uso de sensor MCG &gt; 80% del tiempo (p &lt; 0,005). HbA1c menor se evidenció con culminación del entrenamiento adicional, edad &gt; 18 años, uso de bomba Paradigm 722 con MCG integrado, uso de alarmas por MCG, HbA1c &gt; 7% antes de terapia y controles de glucemia capilar más frecuentes (p &lt; 0,05). Muchos pacientes (45,6%) alcanzaron HbA1c &amp;#8804; 7% con bomba. Conclusiones: La educación, combinada con uso consistente de sensores-MCG y algoritmos de bolos confiere reducciones de HbA1c mayores a las alcanzadas con la terapia solamente con bomba (AU)</dc:description>
<dc:source>Av. diabetol;29(3): 74-80, mayo-jun. 2013. tab, ilus</dc:source>
<dc:identifier>ibc-114142</dc:identifier>
<dc:title xml:lang="es">Factores asociados con el control glucémico óptimo en pacientes tratados con bomba de insulina y monitorización continua de glucosa en tiempo real</dc:title>
<dc:subject>^d1812^s22031</dc:subject>
<dc:subject>^d37656^s22031</dc:subject>
<dc:subject>^d22523^s22074</dc:subject>
<dc:subject>^d7181^s22054</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d22523^s22066</dc:subject>
<dc:subject>^d1812^s22002</dc:subject>
<dc:subject>^d1812^s22044</dc:subject>
<dc:subject>^d22190^s22044</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3946^s22080</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d22190^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d7500^s22044</dc:subject>
<dc:subject>^d23570^s22045</dc:subject>
<dc:subject>^d3944^s22016</dc:subject>
<dc:subject>^d7181^s22080</dc:subject>
<dc:subject>^d50302</dc:subject>
<dc:subject>^d3944^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201306</dc:date>
</metadata>
</record>
</ibecs-document>
